202 related articles for article (PubMed ID: 28416445)
101. Discovery, Characterization, and Engineering of LvIC, an α4/4-Conotoxin That Selectively Blocks Rat α6/α3β4 Nicotinic Acetylcholine Receptors.
Zhu X; Wang S; Kaas Q; Yu J; Wu Y; Harvey PJ; Zhangsun D; Craik DJ; Luo S
J Med Chem; 2023 Feb; 66(3):2020-2031. PubMed ID: 36682014
[TBL] [Abstract][Full Text] [Related]
102. Efficient binding of 4/7 α-conotoxins to nicotinic α4β2 receptors is prevented by Arg185 and Pro195 in the α4 subunit.
Beissner M; Dutertre S; Schemm R; Danker T; Sporning A; Grubmüller H; Nicke A
Mol Pharmacol; 2012 Oct; 82(4):711-8. PubMed ID: 22802270
[TBL] [Abstract][Full Text] [Related]
103. αM-Conotoxin MIIIJ Blocks Nicotinic Acetylcholine Receptors at Neuromuscular Junctions of Frog and Fish.
Rybin MJ; O'Brien H; Ramiro IBL; Azam L; McIntosh JM; Olivera BM; Safavi-Hemami H; Yoshikami D
Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32245200
[TBL] [Abstract][Full Text] [Related]
104. α-Conotoxin as Potential to α7-nAChR Recombinant Expressed in
Liu Y; Yin Y; Song Y; Wang K; Wu F; Jiang H
Mar Drugs; 2020 Aug; 18(8):. PubMed ID: 32806654
[TBL] [Abstract][Full Text] [Related]
105. Alpha-RgIA: a novel conotoxin that specifically and potently blocks the alpha9alpha10 nAChR.
Ellison M; Haberlandt C; Gomez-Casati ME; Watkins M; Elgoyhen AB; McIntosh JM; Olivera BM
Biochemistry; 2006 Feb; 45(5):1511-7. PubMed ID: 16445293
[TBL] [Abstract][Full Text] [Related]
106. Novel small molecule α9α10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats.
Wala EP; Crooks PA; McIntosh JM; Holtman JR
Anesth Analg; 2012 Sep; 115(3):713-20. PubMed ID: 22610850
[TBL] [Abstract][Full Text] [Related]
107. α-Conotoxins Enhance both the In Vivo Suppression of Ehrlich carcinoma Growth and In Vitro Reduction in Cell Viability Elicited by Cyclooxygenase and Lipoxygenase Inhibitors.
Osipov AV; Terpinskaya TI; Yanchanka T; Balashevich T; Zhmak MN; Tsetlin VI; Utkin YN
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32272633
[TBL] [Abstract][Full Text] [Related]
108. On-resin strategy to label α-conotoxins: Cy5-RgIA, a potent α9α10 nicotinic acetylcholine receptor imaging probe.
Muttenthaler M; Nevin ST; Inserra M; Lewis RJ; Adams DJ; Alewood P
Aust J Chem; 2020; 73(4):327-333. PubMed ID: 32394983
[TBL] [Abstract][Full Text] [Related]
109. Rational Design of Potent α-Conotoxin PeIA Analogues with Non-Natural Amino Acids for the Inhibition of Human α9α10 Nicotinic Acetylcholine Receptors.
Li T; Tae HS; Liang J; Zhang Z; Li X; Jiang T; Adams DJ; Yu R
Mar Drugs; 2024 Feb; 22(3):. PubMed ID: 38535451
[TBL] [Abstract][Full Text] [Related]
110. Curare alkaloids from Matis Dart Poison: Comparison with d-tubocurarine in interactions with nicotinic, 5-HT3 serotonin and GABAA receptors.
Spirova EN; Ivanov IA; Kasheverov IE; Kudryavtsev DS; Shelukhina IV; Garifulina AI; Son LV; Lummis SCR; Malca-Garcia GR; Bussmann RW; Hennig L; Giannis A; Tsetlin VI
PLoS One; 2019; 14(1):e0210182. PubMed ID: 30608952
[TBL] [Abstract][Full Text] [Related]
111. Tabernanthalog and ibogainalog inhibit the α7 and α9α10 nicotinic acetylcholine receptors via different mechanisms and with higher potency than the GABA
Tae HS; Ortells MO; Yousuf A; Xu SQ; Akk G; Adams DJ; Arias HR
Biochem Pharmacol; 2024 May; 223():116183. PubMed ID: 38580167
[TBL] [Abstract][Full Text] [Related]
112. Azemiopsin, a Selective Peptide Antagonist of Muscle Nicotinic Acetylcholine Receptor: Preclinical Evaluation as a Local Muscle Relaxant.
Shelukhina IV; Zhmak MN; Lobanov AV; Ivanov IA; Garifulina AI; Kravchenko IN; Rasskazova EA; Salmova MA; Tukhovskaya EA; Rykov VA; Slashcheva GA; Egorova NS; Muzyka IS; Tsetlin VI; Utkin YN
Toxins (Basel); 2018 Jan; 10(1):. PubMed ID: 29316656
[TBL] [Abstract][Full Text] [Related]
113. Role of Cys
Tabassum N; Tae HS; Jia X; Kaas Q; Jiang T; Adams DJ; Yu R
ACS Omega; 2017 Aug; 2(8):4621-4631. PubMed ID: 30023726
[TBL] [Abstract][Full Text] [Related]
114. Design, Synthesis, and Structure-Activity Relationships of Novel Peptide Derivatives of the Severe Acute Respiratory Syndrome-Coronavirus-2 Spike-Protein that Potently Inhibit Nicotinic Acetylcholine Receptors.
Hone AJ; Santiago U; Harvey PJ; Tekarli B; Gajewiak J; Craik DJ; Camacho CJ; McIntosh JM
J Med Chem; 2024 Jun; 67(11):9587-9598. PubMed ID: 38814877
[TBL] [Abstract][Full Text] [Related]
115. Nicotinic acetylcholine receptors.
Wonnacott S; Bermudez I; Millar NS; Tzartos SJ
Br J Pharmacol; 2018 Jun; 175(11):1785-1788. PubMed ID: 29878346
[TBL] [Abstract][Full Text] [Related]
116. The Cyclic Imine Core Common to the Marine Macrocyclic Toxins Is Sufficient to Dictate Nicotinic Acetylcholine Receptor Antagonism.
Bourne Y; Sulzenbacher G; Chabaud L; Aráoz R; Radić Z; Conrod S; Taylor P; Guillou C; Molgó J; Marchot P
Mar Drugs; 2024 Mar; 22(4):. PubMed ID: 38667766
[TBL] [Abstract][Full Text] [Related]
117. Nicotinic Acetylcholine Receptors in the Respiratory Tract.
Hollenhorst MI; Krasteva-Christ G
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684676
[TBL] [Abstract][Full Text] [Related]
118. New Multitarget Molecules Derived from Caffeine as Potentiators of the Cholinergic System.
Munafó JP; Biscussi B; Obiol D; Costabel M; Bouzat C; Murray AP; Antollini S
ACS Chem Neurosci; 2024 Mar; 15(5):994-1009. PubMed ID: 38407056
[TBL] [Abstract][Full Text] [Related]
119. Analgesic conopeptides targeting G protein-coupled receptors reduce excitability of sensory neurons.
Sadeghi M; McArthur JR; Finol-Urdaneta RK; Adams DJ
Neuropharmacology; 2017 Dec; 127():116-123. PubMed ID: 28533165
[TBL] [Abstract][Full Text] [Related]
120. Glycine Receptor Drug Discovery.
Lynch JW; Zhang Y; Talwar S; Estrada-Mondragon A
Adv Pharmacol; 2017; 79():225-253. PubMed ID: 28528670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
